Most importantly, it offers broad NQO1-dependent, tumor-selectivity to BER inhibitors (e.g., MeOX), while eliminating dose-limiting hemolysis and Methemoglobinemia caused by higher ß-lap doses, otherwise required for efficacy. The gene discussed is NQO1; the disease is neoplasm.